Kovitz Investment Group Partners LLC Has $3.14 Million Holdings in Insulet Co. (NASDAQ:PODD)

Kovitz Investment Group Partners LLC decreased its position in Insulet Co. (NASDAQ:PODD - Free Report) by 20.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 12,033 shares of the medical instruments supplier's stock after selling 3,029 shares during the quarter. Kovitz Investment Group Partners LLC's holdings in Insulet were worth $3,141,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of PODD. Baillie Gifford & Co. raised its holdings in shares of Insulet by 3.5% in the fourth quarter. Baillie Gifford & Co. now owns 2,355,683 shares of the medical instruments supplier's stock valued at $614,998,000 after purchasing an additional 79,982 shares during the last quarter. Geode Capital Management LLC increased its stake in Insulet by 2.3% in the 4th quarter. Geode Capital Management LLC now owns 1,779,167 shares of the medical instruments supplier's stock valued at $463,347,000 after buying an additional 40,566 shares during the last quarter. Norges Bank bought a new stake in Insulet during the 4th quarter worth about $248,806,000. Artisan Partners Limited Partnership boosted its stake in shares of Insulet by 24.1% during the 4th quarter. Artisan Partners Limited Partnership now owns 770,188 shares of the medical instruments supplier's stock worth $201,073,000 after buying an additional 149,524 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in shares of Insulet by 1.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 646,959 shares of the medical instruments supplier's stock valued at $168,902,000 after acquiring an additional 10,694 shares in the last quarter.

Insider Transactions at Insulet

In related news, Director Wayne A.I. Frederick sold 1,825 shares of Insulet stock in a transaction on Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total value of $501,875.00. Following the completion of the sale, the director now owns 3,231 shares of the company's stock, valued at approximately $888,525. This trade represents a 36.10 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 0.47% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on PODD shares. StockNews.com cut Insulet from a "buy" rating to a "hold" rating in a report on Tuesday, March 4th. Canaccord Genuity Group lifted their target price on Insulet from $304.00 to $324.00 and gave the stock a "buy" rating in a research note on Friday, February 21st. Citigroup increased their price target on Insulet from $310.00 to $355.00 and gave the company a "buy" rating in a research note on Friday, February 21st. Piper Sandler lifted their price objective on shares of Insulet from $285.00 to $310.00 and gave the stock an "overweight" rating in a research report on Friday, February 21st. Finally, Raymond James reiterated an "outperform" rating and issued a $328.00 price objective (up from $294.00) on shares of Insulet in a report on Friday, February 21st. Four investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $292.06.

Insulet Stock Up 0.5 %

Shares of NASDAQ:PODD opened at $260.71 on Monday. Insulet Co. has a 1 year low of $160.19 and a 1 year high of $289.46. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The business's 50-day moving average is $260.21 and its 200-day moving average is $261.91. The company has a market capitalization of $18.31 billion, a price-to-earnings ratio of 45.03, a P/E/G ratio of 3.62 and a beta of 1.30.

Insulet (NASDAQ:PODD - Get Free Report) last posted its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.00 by $0.15. The firm had revenue of $597.50 million for the quarter, compared to analysts' expectations of $582.02 million. Insulet had a return on equity of 24.46% and a net margin of 20.19%. Equities research analysts predict that Insulet Co. will post 3.92 earnings per share for the current year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.